A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared with a standard PD-1 inhibitor when each was combined with chemotherapy in patients with advanced squamous non-small-cell lung cancer. The drug, ivonescimab, produced a hazard ratio for death of 0.66 in a prespecified interim analysis of the HARMONi-6 phase 3 trial, a randomized, double-blind study conducted across roughly 50 sites in China. The results, set for formal presentation at ASCO 2026 and published simultaneously in The Lancet, represent the first time a bispecific antibody has beaten an established immunotherapy regimen head-to-head on overall survival in this disease.
Why dual PD-1/VEGF blockade changes the calculus in squamous lung cancer
Squamous non-small-cell lung cancer has long been treated differently from its nonsquamous counterpart when it comes to anti-VEGF therapy. Bevacizumab, the most widely used VEGF inhibitor, is generally avoided in squamous histology because of bleeding risks. That left patients with squamous disease relying on PD-1 or PD-L1 checkpoint inhibitors plus platinum-based chemotherapy as first-line treatment, with limited options to layer in vascular targeting. Ivonescimab, developed by Akeso, packages both functions into a single molecule, and the HARMONi-6 data suggest that approach can safely deliver a survival benefit in the very population historically excluded from anti-VEGF strategies.
One plausible biological explanation centers on VEGF-mediated vascular normalization. By partially blocking VEGF signaling, ivonescimab may restructure the chaotic blood vessels inside squamous tumors enough to improve chemotherapy delivery to cancer cells while simultaneously releasing the PD-1 brake on immune attack. If that mechanism is real, it could be confirmed through a future randomized imaging or biomarker substudy measuring tumor perfusion changes and correlating them with treatment response. No such substudy has been reported in the available trial data, so the hypothesis remains untested.
Beyond vascular normalization, dual targeting might also modulate the tumor microenvironment in ways that amplify immune checkpoint blockade. VEGF is known to promote immunosuppressive cell populations such as regulatory T cells and myeloid-derived suppressor cells. By dampening VEGF signaling at the same time as PD-1, ivonescimab could theoretically reduce these suppressive influences and allow cytotoxic T cells to infiltrate more effectively. However, HARMONi-6 did not include detailed immune-correlative analyses in its initial report, leaving these mechanistic ideas as biologically plausible but still speculative.
HARMONi-6 survival data and the strength of the evidence
The interim overall survival analysis reported median OS of approximately 27.9 months in the ivonescimab arm versus 23.7 months in the tislelizumab arm, after a median follow-up of roughly 21.4 months. The hazard ratio for death was 0.66, with a 95% confidence interval of 0.50 to 0.87 and a p-value of 0.0017, according to a regulatory filing from Summit Therapeutics preserved in the SEC’s EDGAR system. The trial used an intention-to-treat population, meaning every randomized patient was counted regardless of whether they completed treatment.
These OS numbers build on an earlier readout that had already established a progression-free survival advantage. That initial analysis showed median PFS of approximately 11.1 months versus 6.9 months, with a hazard ratio of roughly 0.60. The consistency between PFS and OS signals strengthens the case that ivonescimab’s effect on tumor control translated into a genuine extension of life rather than a statistical artifact driven by differences in post-progression therapy.
The comparator arm used tislelizumab, a PD-1 inhibitor approved in China and under review in other markets. Tislelizumab plus chemotherapy is an active, guideline-recognized regimen for first-line squamous NSCLC in China, which makes this a legitimate head-to-head test rather than a comparison against a weak control. The double-blind design further reduces the risk of bias in outcome assessment, and the trial is registered as NCT05840016 on ClinicalTrials.gov.
Statistically, the interim analysis appears robust. The confidence interval around the OS hazard ratio does not cross 1.0, and the p-value meets conventional thresholds for significance. The fact that the survival curves began to separate early and remained apart over time also argues against a late-emerging, fragile benefit. Still, as with any interim look, longer follow-up could slightly shift the absolute medians or hazard ratio, particularly if late toxicities or crossover effects emerge.
Open questions about geography, safety, and global relevance
The most immediate limitation is geography. HARMONi-6 enrolled patients exclusively at sites in China. Regulatory agencies in the United States and Europe have historically required confirmatory data from diverse populations before granting approval, and no protocol-specified global sites or non-Chinese enrollment figures appear in the trial registry or the Lancet publication. Whether ivonescimab’s survival benefit holds across different ethnic backgrounds, treatment patterns, and supportive care standards is an open question that only a multinational trial can answer.
Another consideration is the choice of comparator. While tislelizumab plus chemotherapy is an appropriate standard in China, pembrolizumab-based regimens dominate first-line squamous NSCLC care in many other regions. Without direct comparative data, clinicians will have to infer how ivonescimab stacks up against more globally entrenched PD-1 inhibitors, a process that inevitably introduces uncertainty. Indirect cross-trial comparisons can be misleading because of differences in patient selection, staging methods, and subsequent therapies.
Long-term safety data and patient-reported quality-of-life endpoints also remain incomplete in the available primary sources. Because ivonescimab combines two mechanisms in one molecule, clinicians will want to see detailed adverse-event profiles over extended follow-up, particularly regarding hypertension, proteinuria, and bleeding, all known VEGF-class toxicities that take on added weight in squamous histology. Early reports suggest that grade 3 or higher adverse events were broadly comparable between arms, but the durability of that finding and its impact on daily functioning have not yet been fully characterized.
Quality-of-life outcomes will be especially important if ivonescimab is to be adopted widely. A four-month median survival gain is clinically meaningful, but only if it is not offset by a substantial increase in symptom burden or treatment-related hospitalizations. The trial protocol included patient-reported outcome instruments, yet detailed analyses have not been made public in the sources reviewed. Until those data are available, discussions with patients will necessarily rely on extrapolations from standard PD-1 and VEGF inhibitor experiences rather than ivonescimab-specific evidence.
What the results could mean for practice and future research
If the HARMONi-6 findings are confirmed, ivonescimab could reshape first-line therapy for advanced squamous NSCLC, at least in regions where tislelizumab-based regimens are common. A bispecific that safely incorporates VEGF blockade into a population previously considered poor candidates for anti-angiogenic therapy would fill a long-standing therapeutic gap. For oncologists, the appeal lies in intensifying treatment without adding separate infusions or complicating scheduling, since the dual activity is built into a single antibody.
The trial also offers a broader proof of principle for bispecific immunotherapies in solid tumors. For years, bispecifics have made their biggest impact in hematologic malignancies, particularly B-cell cancers. Demonstrating a clear overall survival advantage over an established checkpoint inhibitor regimen in lung cancer suggests that rationally designed dual-target antibodies could find a place alongside, or even instead of, combination regimens that pair separate monoclonal drugs.
Future research directions are already coming into focus. Multinational trials will be needed to validate efficacy and safety across diverse populations and to satisfy regulators outside China. Mechanistic studies, including imaging of tumor vasculature and immune-cell infiltration, could clarify how much of ivonescimab’s benefit stems from improved drug delivery versus deeper immune activation. Exploratory work in other PD-1–sensitive cancers, such as renal cell carcinoma or hepatocellular carcinoma, may test whether the PD-1/VEGF combination has a class-wide role beyond lung cancer.
For now, HARMONi-6 positions ivonescimab as a compelling new entrant in a crowded immuno-oncology landscape. The bispecific’s ability to extend overall survival while maintaining a tolerable safety profile, at least in an all-Chinese cohort, marks a meaningful advance for patients with advanced squamous NSCLC. The next several years of global development will determine whether that promise translates into a new worldwide standard of care or remains a regionally important, but geographically constrained, option.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
